Have £2k to spend? 2 FTSE 100 dividend stocks for 2020 I’d buy to retire on

Royston Wild picks out two income heroes he’d stash in his shares portfolio for 2020.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Looking for top dividend stocks to load into your ISA for 2020? GlaxoSmithKline (LSE: GSK) is one I’d happily buy on the strength of its product pipeline, one which promises to deliver supreme profits growth through the 2020s and probably beyond.

The Footsie drug giant has around 40 medicines in the development stage in big growth areas like oncology and HIV, a pipeline that is constantly delivering a steady stream of future revenues drivers. And I reckon the business could prove to be a wise pick for 2020 in particular as a backdrop of intense geopolitical and macroeconomic tetchiness boosts demand for safe-haven sectors like pharmaceuticals.

A mix of this rush-to-safety buying and some strong trading releases, such as third-quarter numbers that showed product sales boomed 16% to £9.4bn, has helped Glaxo’s share price also rise 16% so far in the current year. A low forward P/E ratio of 14.4 times gives plenty of room for more strength in the New Year too.

One final thing: at current prices, Glaxo also boasts a bruising 4.6% dividend yield for 2020, created by City expectations of another 80p per share annual payout. But it’s not the only income hero that I’d buy for the year ahead as I reckon National Grid (LSE: GSK) should also attract no shortage of safe-haven buying.

Supercharge your income flows

With a cooling UK (and global) economy raising the likelihood of a rush of profit warnings next year, firms that supply essential services like water, sewage management, electricity and gas are worth their weight in gold. To illustrate this,  National Grid, which operates the country’s vast network of pylons and substations, has seen its share price jump 17% so far in 2019.

There is some regulatory uncertainty here as Labour threatens to nationalise key utilities, but the likely failure of the party to seize power after tomorrow’s general election means that this only major threat to National Grid’s long-term profitability will be taken off the table.

Illustrating the company’s quality as a solid earnings generator even in tough economic times, City forecasts suggest that the network operator will follow a predicted 33% bottom-line rise in the current fiscal year (to March 2020) with an additional 6% advance in the following period. And as you’d expect, this leads to expectations of further dividend growth too.

Last year’s 47.34p per share total dividend is anticipated to rise to 48.7p in the present period and then to 50.1p in financial 2021, estimates that yield a mighty 5.5% and 5.6% respectively. But this is not the only reason to celebrate National Grid at current prices as it also commands an undemanding forward P/E ratio of 15.1 times, one that fails to fully reflect its supreme defensive qualities and leaves much scope for share price gains in the new calendar year.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Fireworks display in the shape of willow at Newcastle, Co. Down , Northern Ireland at Halloween.
Investing Articles

The Anglo American share price soars to £25, but I’m not selling!

On Thursday, the Anglo American share price soared after mega-miner BHP Group made an unsolicited bid for it. But I…

Read more »

Investing Articles

Now 70p, is £1 the next stop for the Vodafone share price?

The Vodafone share price is back to 70p, but it's a long way short of the 97p it hit in…

Read more »

Concept of two young professional men looking at a screen in a technological data centre
Investing Articles

If I’d put £5,000 in Nvidia stock at the start of 2024, here’s what I’d have now

Nvidia stock was a massive winner in 2023 as the AI chipmaker’s profits surged across the year. How has it…

Read more »

Light bulb with growing tree.
Investing Articles

3 top investment trusts that ‘green’ up my Stocks and Shares ISA

I’ll be buying more of these investment trusts for my Stocks and Shares ISA given the sustainable and stable returns…

Read more »

Investing Articles

8.6% or 7.2%? Does the Legal & General or Aviva dividend look better?

The Aviva dividend tempts our writer. But so does the payout from Legal & General. Here he explains why he'd…

Read more »

a couple embrace in front of their new home
Investing Articles

Are Persimmon shares a bargain hiding in plain sight?

Persimmon shares have struggled in 2024, so far. But today's trading update suggests sentiment in the housing market's already improving.

Read more »

Market Movers

Here’s why the Unilever share price is soaring after Q1 earnings

Stephen Wright isn’t surprised to see the Unilever share price rising as the company’s Q1 results show it’s executing on…

Read more »

Investing Articles

Barclays’ share price jumps 5% on Q1 news. Will it soon be too late to buy?

The Barclays share price has been having a great time this year, as a solid Q1 gives it another boost.…

Read more »